Semaglutide: A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
This article will provide an overview of the GLP-1 receptor agonists, including the pharmacology of semaglutide, its clinical evidence and role in therapy in type 2 DM.
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
More News: Byetta | Cardiology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Heart | Hormones | Insulin | Pancreas | Stroke